TABLE OF CONTENTS
1 INTRODUCTION 23
1.1 OBJECTIVES OF THE STUDY 23
1.2 MARKET DEFINITION 23
1.3 OVERVIEW 23
1.4 LIMITATIONS 25
1.5 MARKETS COVERED 25
2 MARKET SEGMENTATION 27
2.1 MARKETS COVERED 27
2.2 GEOGRAPHICAL SCOPE 28
2.3 YEARS CONSIDERED FOR THE STUDY 29
2.4 CURRENCY AND PRICING 29
2.5 DBMR TRIPOD DATA VALIDATION MODEL 30
2.6 MULTIVARIATE MODELLING 33
2.7 PRODUCT TYPE LIFELINE CURVE 33
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 34
2.9 DBMR MARKET POSITION GRID 35
2.10 MARKET END USER COVERAGE GRID 36
2.11 VENDOR SHARE ANALYSIS 37
2.12 SECONDARY SOURCES 38
2.13 ASSUMPTIONS 38
3 EXECUTIVE SUMMARY 39
4 PREMIUM INSIGHTS 42
4.1 PORTERS FIVE FORCES MODEL 45
4.2 PESTEL ANALYSIS 46
5 INDUSTRY INSIGHTS: GLOBAL NASAL SPRAY MARKET 47
5.1 INDUSTRY INSIGHTS 47
6 REGULATIONS: GLOBAL NASAL SPRAY MARKET 48
6.1 REGULATORY SCENARIO IN THE U.S. 48
6.2 REGULATORY SCENARIO IN EUROPE 49
6.3 REGULATORY SCENARIO IN INDIA 50
6.4 REGULATORY SCENARIO IN CHINA 50
7 MARKET OVERVIEW 51
7.1 DRIVERS 53
7.1.1 INCREASE IN INFECTION AND ALLERGIC CASES 53
7.1.2 RISING PREVALENCE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA 53
7.1.3 EFFECTIVENESS OVER OTHER FORMS OF DRUG DELIVERY 54
7.1.4 IMPROVING PATIENT COMPLIANCE AND ACCEPTABILITY 55
7.2 RESTRAINTS 56
7.2.1 PRODUCT RECALLS 56
7.2.2 ADVERSE EFFECTS OF USING NASAL SPRAYS 57
7.3 OPPORTUNITIES 58
7.3.1 NEW RISING DEMAND FOR SELF-ADMINISTRATIVE DRUG DELIVERY 58
7.3.2 EXPANDING THERAPEUTIC APPLICATIONS FOR NASAL SPRAYS 58
7.3.3 STRATEGIC INITIATIVES TAKEN BY KEY MARKET PLAYERS 59
7.4 CHALLENGES 59
7.4.1 REGULATORY HURDLES 59
7.4.2 ADDICTION TO NASAL SPRAY 60
8 GLOBAL NASAL SPRAY MARKET, BY PRODUCT TYPE 61
8.1 OVERVIEW 62
8.2 DECONGESTION NASAL SPRAY 65
8.3 STEROID NASAL SPRAY 66
8.4 SALT WATER SOLUTION/SALINE NASAL SPRAY 67
8.5 OTHERS 68
9 GLOBAL NASAL SPRAY MARKET, BY CONTAINER DESIGN 69
9.1 OVERVIEW 70
9.2 PUMP BOTTLES 73
9.3 PRESSURIZED CANISTERS 74
10 GLOBAL NASAL SPRAY MARKET, BY DOSAGE FORM 75
10.1 OVERVIEW 76
10.2 MULTI DOSE 79
10.3 UNIT/SINGLE DOSE 80
10.4 BI DOSE 81
11 GLOBAL NASAL SPRAY MARKET, BY THERAPEUTIC CLASS 83
11.1 OVERVIEW 84
11.2 ANTIHISTAMINE 87
11.3 NASAL STEROIDS 88
11.4 MAST CELL INHIBITOR 89
11.5 ANTICHOLINERGIC 90
12 GLOBAL NASAL SPRAY MARKET, BY APPLICATION 91
12.1 OVERVIEW 92
12.2 NASAL CONGESTION 95
12.3 ALLERGIC AND NON-ALLERGIC RHINITIS 96
12.4 CENTRAL NERVOUS SYSTEM DISORDERS 97
12.5 VACCINATION 98
12.6 OTHERS 99
13 GLOBAL NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY 100
13.1 OVERVIEW 101
13.2 PRESCRIBED 104
13.3 OVER THE COUNTER 105
14 GLOBAL NASAL SPRAY MARKET, BY END USER 107
14.1 OVERVIEW 108
14.2 HOME CARE SETTINGS 111
14.3 HOSPITALS 112
14.4 CLINICS 113
14.5 COMMUNITY HEALTH CARE 114
15 GLOBAL NASAL SPRAY MARKET, BY REGION 115
15.1 OVERVIEW 116
15.2 NORTH AMERICA 122
15.2.1 U.S. 129
15.2.2 CANADA 131
15.2.3 MEXICO 133
15.3 EUROPE 135
15.3.1 GERMANY 143
15.3.2 U.K. 145
15.3.3 FRANCE 147
15.3.4 ITALY 149
15.3.5 SPAIN 151
15.3.6 SWITZERLAND 153
15.3.7 NETHERLANDS 155
15.3.8 BELGIUM 157
15.3.9 RUSSIA 159
15.3.10 TURKEY 161
15.3.11 REST OF EUROPE 163
15.4 ASIA-PACIFIC 164
15.4.1 CHINA 172
15.4.2 JAPAN 174
15.4.3 INDIA 176
15.4.4 AUSTRALIA 178
15.4.5 SOUTH KOREA 180
15.4.6 MALAYSIA 182
15.4.7 THAILAND 184
15.4.8 SINGAPORE 186
15.4.9 INDONESIA 188
15.4.10 PHILIPPINES 190
15.4.11 REST OF ASIA-PACIFIC 192
15.5 SOUTH AMERICA 193
15.5.1 BRAZIL 200
15.5.2 ARGENTINA 202
15.5.3 REST OF SOUTH AMERICA 204
15.6 MIDDLE EAST AND AFRICA 205
15.6.1 SOUTH AFRICA 212
15.6.2 UAE 214
15.6.3 SAUDI ARABIA 216
15.6.4 REST OF MIDDLE EAST & AFRICA 218
16 GLOBAL NASAL SPRAY MARKET, COMPANY LANDSCAPE 219
16.1 COMPANY SHARE ANALYSIS: GLOBAL 219
16.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 220
16.3 COMPANY SHARE ANALYSIS: EUROPE 221
16.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 222
17 SWOT ANALYSIS 223
18 COMPANY PROFILE 224
18.1 GLAXOSMITHKLINE PLC. 224
18.1.1 COMPANY SNAPSHOT 224
18.1.2 REVENUE ANALYSIS 224
18.1.3 COMPANY SHARE ANALYSIS 225
18.1.4 PRODUCT PORTFOLIO 225
18.1.5 RECENT DEVELOPMENTS 225
18.2 PFIZER INC. 227
18.2.1 COMPANY SNAPSHOT 227
18.2.2 REVENUE ANALYSIS 227
18.2.3 COMPANY SHARE ANALYSIS 228
18.2.4 PRODUCT PORTFOLIO 228
18.2.5 RECENT DEVELOPMENTS 228
18.3 EMERGENT 230
18.3.1 COMPANY SNAPSHOT 230
18.3.2 REVENUE ANALYSIS 230
18.3.3 COMPANY SHARE ANALYSIS 231
18.3.4 PRODUCT PORTFOLIO 231
18.3.5 RECENT DEVELOPMENT 231
18.4 SANDOZ INTERNATIONAL GMBH (A PART OF NOVARTIS) 232
18.4.1 COMPANY SNAPSHOT 232
18.4.2 REVENUE ANALYSIS 232
18.4.3 COMPANY SHARE ANALYSIS 233
18.4.4 PRODUCT PORTFOLIO 233
18.4.5 RECENT DEVELOPMENT 233
18.5 CATALENT, INC. 234
18.5.1 COMPANY SNAPSHOT 234
18.5.2 REVENUE ANALYSIS 234
18.5.3 COMPANY SHARE ANALYSIS 235
18.5.4 PRODUCT PORTFOLIO 235
18.5.5 RECENT DEVELOPMENTS 235
18.6 AYTU HEALTH (A SUBSIDIARY OF AYTU BIOPHARMA, INC.) 237
18.6.1 COMPANY SNAPSHOT 237
18.6.2 REVENUE ANALYSIS 237
18.6.3 PRODUCT PORTFOLIO 238
18.6.4 RECENT DEVELOPMENTS 238
18.7 AISHWARYA GROUP 239
18.7.1 COMPANY SNAPSHOT 239
18.7.2 PRODUCT PORTFOLIO 239
18.7.3 RECENT DEVELOPMENTS 239
18.8 ASSERTIO THERAPEUTICS, INC. 240
18.8.1 COMPANY SNAPSHOT 240
18.8.2 REVENUE ANALYSIS 240
18.8.3 PRODUCT PORTFOLIO 241
18.8.4 RECENT DEVELOPMENT 241
18.9 AURENA LABORATORIES. 242
18.9.1 COMPANY SNAPSHOT 242
18.9.2 PRODUCT PORTFOLIO 242
18.9.3 RECENT DEVELOPMENTS 242
18.10 BAYER AG 244
18.10.1 COMPANY SNAPSHOT 244
18.10.2 REVENUE ANALYSIS 244
18.10.3 COMPANY SHARE ANALYSIS 245
18.10.4 PRODUCT PORTFOLIO 245
18.10.5 RECENT DEVELOPMENTS 245
18.11 CIPLA INC. 247
18.11.1 COMPANY SNAPSHOT 247
18.11.2 REVENUE ANALYSIS 247
18.11.3 PRODUCT PORTFOLIO 248
18.11.4 RECENT DEVELOPMENT 248
18.12 J PHARMACEUTICALS. 249
18.12.1 COMPANY SNAPSHOT 249
18.12.2 PRODUCT PORTFOLIO 249
18.12.3 RECENT DEVELOPMENTS 249
18.13 LEEFORD HEALTHCARE LTD 250
18.13.1 COMPANY SNAPSHOT 250
18.13.2 PRODUCT PORTFOLIO 250
18.13.3 RECENT DEVELOPMENTS 250
18.14 ST. RENATUS. 251
18.14.1 COMPANY SNAPSHOT 251
18.14.2 PRODUCT PORTFOLIO 251
18.14.3 RECENT DEVELOPMENTS 251
18.15 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD) 252
18.15.1 COMPANY SNAPSHOT 252
18.15.2 REVENUE ANALYSIS 252
18.15.3 PRODUCT PORTFOLIO 253
18.15.4 RECENT DEVELOPMENTS 253
18.16 ULTRATECH INDIA LIMITED 254
18.16.1 COMPANY SNAPSHOT 254
18.16.2 PRODUCT PORTFOLIO 254
18.16.3 RECENT DEVELOPMENTS 254
18.17 VIATRIS INC. 255
18.17.1 COMPANY SNAPSHOT 255
18.17.2 REVENUE ANALYSIS 255
18.17.3 COMPANY SHARE ANALYSIS 256
18.17.4 PRODUCT PORTFOLIO 256
18.17.5 RECENT DEVELOPMENT 256
19 QUESTIONNAIRE 257
20 RELATED REPORTS 261

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.